These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10428934)

  • 1. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
    Palmer S; Shafer RW; Merigan TC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2046-50. PubMed ID: 10428934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
    Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1167-73. PubMed ID: 11522186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
    Hossain MM; Coull JJ; Drusano GL; Margolis DM
    Antiviral Res; 2002 Jul; 55(1):41-52. PubMed ID: 12076750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
    Foli A; Sogocio KM; Anderson B; Kavlick M; Saville MW; Wainberg MA; Gu Z; Cherrington JM; Mitsuya H; Yarchoan R
    Antiviral Res; 1996 Oct; 32(2):91-8. PubMed ID: 8891168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.
    Srinivas RV; Fridland A
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1484-7. PubMed ID: 9624498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
    Cihlar T; Birkus G; Greenwalt DE; Hitchcock MJ
    Antiviral Res; 2002 Apr; 54(1):37-45. PubMed ID: 11888656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
    Wainberg MA; Miller MD; Quan Y; Salomon H; Mulato AS; Lamy PD; Margot NA; Anton KE; Cherrington JM
    Antivir Ther; 1999; 4(2):87-94. PubMed ID: 10682153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
    Boelaert JR; Sperber K; Piette J
    AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1241-7. PubMed ID: 10505672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
    Parkin N; Chappey C; Maroldo L; Bates M; Hellmann NS; Petropoulos CJ
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):128-36. PubMed ID: 12394790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
    Cherrington JM; Mulato AS; Fuller MD; Chen MS
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2212-6. PubMed ID: 8878611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
    Suo Z; Johnson KA
    J Biol Chem; 1998 Oct; 273(42):27250-8. PubMed ID: 9765248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
    Mulato AS; Cherrington JM
    Antiviral Res; 1997 Nov; 36(2):91-7. PubMed ID: 9443665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
    Harrigan PR; Miller MD; McKenna P; Brumme ZL; Larder BA
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1067-72. PubMed ID: 11897591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
    Stone C; Ait-Khaled M; Craig C; Griffin P; Tisdale M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
    Bridges CG; Taylor DL; Ahmed PS; Brennan TM; Hornsperger JM; Navé JF; Casara P; Tyms AS
    Antimicrob Agents Chemother; 1996 May; 40(5):1072-7. PubMed ID: 8723443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.